Portal de Periódicos da CAPES

Inflammatory mediators of asthma

1988; Wiley; Volume: 4; Issue: 4 Linguagem: Inglês

10.1002/ppul.1950040409

8755-6863

William M. Abraham, Adam Wanner,

Respiratory and Cough-Related Research

Pediatric PulmonologyVolume 4, Issue 4 p. 237-247 State of the Art Review Inflammatory mediators of asthma Dr William M. Abraham Phd, Corresponding Author Dr William M. Abraham Phd Division of Pulmonary Disease, Harry Pearlman Biomedical Research Institute, University of Miami at Mount Sinai Medical Center, Miami Beach, FloridaDivision of Pulmonary Disease, Mount Sinai Medical Center, 4300 Alton Road, Miami Beach, FL 33140Search for more papers by this authorAdam Wanner MD, Adam Wanner MD Division of Pulmonary Disease, Harry Pearlman Biomedical Research Institute, University of Miami at Mount Sinai Medical Center, Miami Beach, FloridaSearch for more papers by this author Dr William M. Abraham Phd, Corresponding Author Dr William M. Abraham Phd Division of Pulmonary Disease, Harry Pearlman Biomedical Research Institute, University of Miami at Mount Sinai Medical Center, Miami Beach, FloridaDivision of Pulmonary Disease, Mount Sinai Medical Center, 4300 Alton Road, Miami Beach, FL 33140Search for more papers by this authorAdam Wanner MD, Adam Wanner MD Division of Pulmonary Disease, Harry Pearlman Biomedical Research Institute, University of Miami at Mount Sinai Medical Center, Miami Beach, FloridaSearch for more papers by this author First published: 1988 https://doi.org/10.1002/ppul.1950040409Citations: 4AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat References 1 Barnes PJ. The third nervous system in the lung: Physiology and clinical perspectives. Thorax. 1984; 39: 561–567. 2 Howarth PH. The mast cell as a primary effector cell in the pathogenesis of asthma. J Allergy Clin Immunol. 1986; 77: 274–282. 3 Schleimer R, Fox C, Naclerio R. Role of human basophils and mast cells in the pathogenesis of allergic diseases. J Allergy Clin Immunol. 1985; 76: 369–374. 4 Scott WA, Rouzer CA, Cohn ZA. Leukotriene C release by macrophages. Fed Proc. 1983; 42: 129–133. 5 Frigas E, Gleich CJ. The eosinophil and the pathophysiology of asthma. J Allergy Clin Immunol. 1986; 77: 527–537. 6 Murphy KR, Wilson MC, Irvin CG, Glezen LS, Marsh WR, Haslett C, Henson PM, Larsen GL. The requirement for polymorphonuclear leukocytes in the late asthmatic response and heightened airways reactivity in an animal model. Am Rev Respir Dis. 1986; 134: 62–68. 7 Morley J, Sanjar S, Page CP. The platelet in asthma. Lancet. 1984; 12: 1142–1154. 8 Liu MC, Proud D, Lichtenstein LM, Mac Glashan DW Jr, Schleimer RP, Adkinson NF Jr, Kagey-Sobotka AK, Schulman ES, Plaut M. Human lung macrophage-derived histamine-releasing activity is due to IgE-dependent factors. J Immunol. 1986; 136: 2588–2595. 9 de Monchy JGR, Kauffman HF, Venge P, Koeter GH, Jansen HM, Sluiter HJ, de Vries K. Bronchoalveolar eosinophilia during allergen-induced late asthmatic reactions. Am Rev Respir Dis. 1985; 373–376. 10 de Monchy JGR, Kauffman HF, Venge P, Koeter GH, de Vries K. Bronchoalveolar lavage and the late asthmatic reaction. In: Asthma. Clinical Pharmacology and Therapeutic Progress. Oxford: Blackwell Scientific. 1986; 6–57. 11 Nadel JA. Inflammation and asthma. J Allergy Clin Immunol. 1984; 73: 651–653. 12 Ishizaka K, Ishizaka T. Triggering of histamine release from rat mast cells by divalent antibodies against IgE receptors. J Immunol. 1978; 120: 800–805. 13 Morita Y, Chiang PK, Siraganian RP. Effect of inhibitors of transmethylation on histamine release from human basophils. Biochem Pharmacol. 1981; 30: 785–791. 14 Morita Y, Siraganian RP. Inhibition of IgE mediated histamine release from rat basophilic leukemia cells and rat mast cells by inhibitors of transmethylation. J Immunol. 1981; 127: 1339–1344. 15 Chiang PK, Richards HH, Canteri GL. S-adenosyl-L-homocysteine hydrolase: Analogues of S-adenosyl-L-homocysteine as potential inhibitors. Mol Pharmacol. 1977; 13: 939–947. 16 Hirata F, Axelrod J, Crews FT. Concanavalin A stimulates phospholipid methylation and phosphatidylserine decarboxylation in rat mast cells. Proc Natl Acad Sci USA. 1979; 76: 4813–4816. 17 Anderson WH. Biochemical mediators: Release, chemistry, and function. In: Bronchial Asthma: Mechanisms and Therapeutics. Boston/Toronto: Little, Brown and Co. 1985; 57–87. 18 Dyer J, Warren K, Merlin S, Metcalfe DD, Kaliner M. Measurement of plasma histamine: Description of an improved method and normal values. J Allergy Clin Immunol. 1982; 70: 82–87. 19 Durham SR, Lee TH, Cromwell O, Shaw RJ, Merrett TG, Merrett J, Cooper P, Kay AB. Immunologic studies in allergeninduced late-phase asthmatic reactions. J Allergy Clin Immunol. 1984; 74: 49–60. 20 Atkins PC, Rosenblum F, Dunsky EH, Coffey R, Zweiman B. Comparison of plasma histamine and cyclic nucleotides after antigen and methacholine inhalation in man. J Allergy Clin Immunol. 1980; 66: 478–485. 21 Bhat KM, Arroyave CM, Marney SR, Stevenson DD, Tan EM. Plasma histamine changes during provoked bronchospasm in asthmatic patients. J Allergy Clin Immunol. 1976; 58: 647–656. 22 Barnes P, Fitzgerald G, Brown MJ, Dollery C. Nocturnal asthma and changes in circulating epinephrine, histamine and cortisol. New Engl J Med. 1980; 303: 263–267. 23 Eyre P. Pulmonary histamine H1 and H2 receptor studies. In: Asthma: Physiology, Immunopharmacology and Treatment. New York: Academic Press. 1977; 169–180. 24 Nadel JA, Davis B. Autonomic regulation of mucus secretion and ion transport in airways. Asthma Physiol Immunopharmacol. 1978; 112: 829–859. 25 Shelhamer JH, Marom Z, Kaliner M. Immunologic and neuropharmacologic stimulation of mucous glycoprotein release from human airways in vitro. J Clin Invest. 1980; 66: 1400–1408. 26 Wanner A, Zarzecki S, Hirsch J, Epstein S. Tracheal mucous transport in experimental canine asthma. – Appl Physiol. 1975; 39: 950–957. 27 Ahmed T, Mirbahar VB, Oliver W Jr, Eyre P, Wanner A. Characterization of the H1 and H2 receptor function in pulmonary and systemic circulation of sheep. J Appl Physiol. 1982; 53: 175–184. 28 Wasserman SI. Mediators of immediate hypersensitivity. J Allergy Clin Immunol. 1983; 72: 101–115. 29 Chiesa A, Dain D, Meyers GL, Kessler GF, Gold WM. Histamine release during antigen inhalation in experimental asthma in dogs. Am Rev Respir Dis. 1975; 111: 148–156. 30 Wanner A, Mezey RJ, Reinhart M, Eyre P. Antigen-induced bronchospasm in conscious sheep. J Appl Physiol. 1979; 47: 917–922. 31 Patterson R, Harris K, Suszko IM, Roberts M. Reagin-mediated asthma in rhesus monkeys and relation to bronchial cell histamine release and airway reactivity to carbocholine. J Clin Invest 1976; 57: 586–593. 32 Abraham WM, Oliver W Jr, King MM, Yerger L, Wanner A. Effect of pharmacologic agents on antigen-induced decreases in specific lung conductance in sheep. Am Rev Respir Dis. 1981; 124: 554–558. 33 Russi EW, Perruchoud AP, Yerger LD, Stevenson JS, Tabak J, Marchette B. Abraham, WM. Late phase bronchial obstruction following nonimmunologic mast cell degranulation. J Appl Physiol. 1984; 57: 1182–1188. 34 Abraham WM. The importance of lipoxygenase products of arachidonic acid in allergen-induced late responses. Am Rev Respir Dis. 1987; 135: 549–553. 35 Popa VT. Effect of an H1 blocker, chlorpheniramine, on inhalation tests with histamine and allergen in allergic asthma. Chest. 1980; 78: 442–451. 36 Booij-Noord H, Orie NGM, de Vries K. Immediate and late bronchial obstructive reactions to inhalation of house dust and protective effects of disodium cromoglycate and prednisolone. J Allergy Clin Immunol. 1971; 48: 344–354. 37 Delehunt JC, Perruchoud AP, Yerger L, Marchette B, Stevenson JS, Abraham WM. The role of slow-reacting substance of anaphylaxis in the late bronchial response after antigen challenge in allergic sheep. Am Rev Respir Dis. 1984; 130: 748–754. 38 Keyzer JJ, Kauffman HF, de Monchy JGR, Keyzer-Udding JJ, de Vries K. Urinary Nδ-methylhistamine during early and late allergen-induced bronchial-obstructive reactions. J Allergy Clin Immunol. 1984; 74: 240–245. 39 Holgate ST, Emanuel MB, Howarth PH. Astemizole and other H1-antihistaminic drug treatment of asthma. J Allergy Clin Immunol (Suppl). 1985; 76: 375–380. 40 Demopoulos CA, Pinckard RN, Hanahan DJ. Platelet-activating factor. Evidence for 1–0-alkyl-2-acetyl-sn-glyceryl-3-phosphorylcholine as the active component (a new class of lipid chemical mediators). J Biol Chem. 1979; 254: 9355–9358. 41 Benveniste J, Tence M, Varenne J, Bidault C, Boullet C, Polonsky J. Semi-synthese et structure propossee du facteur activant les plaquettes (PAF): PAF-acether, un alkyl-ether analogue de la lysophosphatidylcholine. CR Acad Sci. 1979; 289: 1017–1021. 42 Lotner GZ, Lynch JM, Betz SJ, Henson PM. Human neutrophil-derived platelet-activating factor. J Immunol. 1980; 124: 676–684. 43 Benveniste J, Henson PM, Cochrane CG. Leukocyte-dependent histamine release from rabbit platelets: The role of IgE, basophils and a platelet-activating factor. J Exp Med. 1972; 136: 1356–1377. 44 Elias DJ, Valone FH, Lazarus SC, Gold WM. Dog mastocytoma cells produce pellet-associated platelet activating factor (PAF) and lyso-PAF. Physiologist. 1986; 29: 167. 45 Lee TC, Lenihan DJ, Malone B, Roddy LL, Wasserman SI. Increased biosynthesis of platelet-activating factor in activated human eosinophils. J Biol Chem. 1984; 259: 5526–5530. 46 Lewis RA, Goetzl EJ, Wasserman SI, Valone FH, Rubin RH, Austen KF. The release of four mediators of immediate hypersensitivity from human leukemic basophils. J Immunol. 1975; 114: 87–92. 47 Mencia-Huerta JM, Benhamou M. PAF-acether (platelet activating factor): An update. In: Asthma: Clinical Pharmacology and Therapeutic Progress. Oxford: Blackwell Scientific. 1986; 237–250. 48 Benveniste J, et al. Biosynthesis of platelet activating factor (PAF-acether). II. Involvement of phospholipase A2 in the formation of PAF-acether and lyso-PAF-acether from rabbit platelets. Thromb Res. 1982; 25: 375–385. 49 Bessin P, Bennet J, Apffel D, Desgux L, Pelas I, Benveniste J. Acute circulatory collapse caused by platelet activating factor in (PAF-acether) in dogs. Eur J Pharmacol. 1983; 86: 403–413. 50 Denjean A, Arnoux B, Masse R, Lockhart A, Benveniste J. Acute effects of intratracheal administration of platelet-activating factor in baboons. J Appl Physiol. 1983; 55: 799–804. 51 Gateau O, Arnoux B, Deriaz H, Viars P, Benveniste J. Acute effects of intratrachial administration of PAF-acether (plateletactivating factor) in humans. Am Rev Respir Dis. 1984; 129: A3. 52 Basran GS, Page CP, Paul W, Merley J. Cromoglycate (DSCG) inhibits responses to platelet-activating factor (PAF-acether) in man: An alternative mode of action for DSCG in asthma? Eur J Pharmacol. 1983; 86: 143–144. 53 Vargaftig BB, Lefort J, Chignard M, Benveniste J. Plateletactivating factor induces a platelet dependent bronchoconstriction unrelated to the formation of prostaglandin derivatives. Eur J Pharmacol. 1980; 65: 185–192. 54 Mazzoni L, Morley J, Page CP, Sanjar S. Induction of airway hyperreactivity by platelet activating factor in the guinea pig. J Physiol. 1985; 365–107. 55 Chung KF, Aizawa H, Leikauf GD, Ueki IF, Evans TW, Hirose T, Nadel JA. Airway hyperresponsiveness induced by plateletactivating factor: Role of thromboxane generation. J Pharmacol Exp Ther. 1986; 236: 580–584. 56 Cuss FM, Dixon CMS, Barnes PJ. Effects of inhaled platelet activating factor on pulmonary function and bronchial responsiveness in man. Lancet. 1986; 2: 189–192. 57 Camussi G, Pawlowski I, Telta C, Roffirello C, Alberton M, Brentjeus J, Andres G. Acute lung inflammation induced in the rabbit by local instillation of 1–0-octadecyl 2-acetyl-syn-glycerl-3-phosphonylcholine or of native platelet activating factor. Am J Pathol. 1983; 112: 78–88. 58 Holgate ST, Burns GB, Robinson C, Church MK. Anaphylactic and calcium-dependent generation of prostaglandin D2 (PGD2), thromboxane B2 and other cyclooxygenase products of arachidonic acid by dispersed human lung cells and relationship to histamine release. J Immunol. 1984; 133: 2138–2144. 59 Schulman ES, Newball HH, Demers LM, Fitzpatrick FA, Adkinson NF Jr. Anaphylactic release of thromboxane A2, prostaglandin D2, and prostacyclin from human lung parenchyma. Am Rev Respir Dis. 1981; 124: 402–406. 60 Hardy CC, Robinson C, Tattersfield AE, Holgate ST. The bronchoconstrictor effect of inhaled prostaglandin D2 in normal and asthmatic men. New Engl J Med. 1984; 311: 209–213. 61 Wasserman M, Griffen RL, Marsalisi FB. Potent bronchoconstrictor effects of aerosolized prostaglandin D2 in dogs. Prostaglandins. 1980; 20: 703–715. 62 Patterson R, Harris KE, Greenberger PA. Effect of prostaglandin D2 and I2 on the airways of rhesus monkeys. J Allergy Clin Immunol. 1980; 65: 269–273. 63 Shephard EG, Malan L, MacFarlane CM, Mouton W, Joubert JR. Lung function and plasma levels of thromboxane B2, 6- ketoprostaglandin F1 and B-thrombogobulin in antigen-induced asthma before and after indomethacin pretreatment. Br J Clin Pharmacol. 1985; 19: 459–470. 64 Aizawa H, Chung KF, Leikauf GD. et al. Significance of thromboxane generation in ozone-induced airway hyperresponsiveness in dogs. J Appl Physiol. 1985; 59: 1918–1923. 65 Chung KF, Aizawa H, Becker AB, Frick O, Gold WM, Nadel JA. Inhibition of antigen-induced airway hyperresponsiveness by a thromboxane synthetase inhibitor (OKY-046) in allergic dogs. Am Rev Respir Dis. 1986; 134: 258–261. 66 Halonen M, Lohman IC, Dunn AM, McManus LM, Palmer JD. Participation of platelets in the physiologic alterations of the AGEPC response and of IgE anaphylaxis in the rabbit: Effects of PGI2 inhibition of platelet function. Am Rev Respir Dis. 1985; 131: 11–17. 67 Bianco S, Robuschi M, Cesarani R, Gandolfi C, Kamburoff P. Prevention of a specifically induced bronchoconstrictor by PGI2 and 20-methyl-PGI2 in asthmatic patients. Pharmacol Res Commun. 1978; 10: 657–675. 68 Bach MK, Brashler JR, Smith HW, Fitzpatrick FA, Sun FF, McGuire JC. 6,9-Deepoxy-6,9-(phenylimino)-6,8-prostaglandin I1, (U-60,257), a new inhibitor of leukotriene C and D synthesis: In vitro studies. Prostaglandins. 1982; 23: 759–771. 69 Sun FF, McGuire JC. Inhibition of human neutrophil arachidonate 5-lipoxygenase by 6,9-deepoxy-6,9-(phenylimino)-6,8-prostaglandin I1, (U-60,257). Prostaglandins. 1983; 26: 211–221. 70 Robinson C, Holgate ST. Modulation of arachidonic acid metabolism in dispersed human lung cells by the inhibitor of leukotriene formation U-60,257 (Piriprost). Prostaglandins. 1984; 28: 548. 71 Johnson JG, McNee ML, Bach MK, Smith HW. The activity of a new, novel inhibitor of leukotriene synthesis in rhesus monkey Ascaris reaction. Int Arch Allergy Appl Immunol. 1983; 70: 169. 72 Murphy RC, Hammarstrom S, Samuelsson B. Leukotriene C: A slow reacting substance from murine mastocytoma cells. Proc Natl Acad Sci USA 1979; 76: 4275–4279. 73 Orning L, Hammarstrom S, Samuelsson B. A slow reacting substance from rat basophilic leukemia cells. Proc Natl Acad Sci USA 1980; 77: 2014–2017. 74 Lewis RA, Austen KF, Drazen JM, Clark DA, Corey EJ. Slow reacting substance of anaphylaxis: Identification of leukotrienes C-1 and D from human and rat sources. Proc Natl Acad Sci USA 1980; 77: 3710–3714. 75 Morris HR, Taylor GW, Piper PJ, Tippins JR. Structure of slow-reacting substance of anaphylaxis from guinea pig lung. Nature (London). 1980; 285: 204–205. 76 Lewis RA, Drazen JM, Austen KF, Clark DA, Corey EJ. Identification of the C(6)-S-conjugate of leukotriene A with cysteine as a naturally-occurring slow reacting substance of anaphylaxis (SRS-A). Importance of the 11-cis-geometry for biological activity. Biochem Biophys Res Commun. 1980; 96: 271–277. 77 Verhagen J, Bruynzeel Pieter LB, Koedam JA, Wassink GA, de Boer M, Terpstra GK, Kreukniet J, Veldink GA, Vliegenthart JFG. Specific leukotriene formation by purified human eosinophils and neutrophils. Fed Eur Biochem Soc. 1984; 168: 23–28. 78 Bonney RJ, Opas EE, Humes JL. Lipoxygenase pathways of macrophages. Fed Proc. 1985; 44: 2933–2936. 79 Ford-Hutchinson AW. Leukotrienes: Their formation and role as inflammatory mediators. Fed Proc. 1985; 44: 25–29. 80 Soter NA, Lewis RA, Corey EJ, Austen KF. Local effects of synthetic leukotrienes (LTC4, LTD4, LTE4, and LTB4) in human skin. J Invest Dermatol. 1983; 80: 115–119. 81 Staub NC, Schultz EL, Koike K, Albertine KH. Effect of neutrophil migration induced by leukotriene B4 on protein permeability in sheep lung. Fed Proc 1985; 44: 30–35. 82 Hamel R, Ford-Hutchinson AW. Bronchoconstrictor effects of leukotriene B4 in the guinea pig in vivo. Prostaglandins. 1983; 25: 405–412. 83 O'Byrne PM, Leikauf GD, Aizawa H, Bethel RA, Ueki IF, Holtzman MJ, Nadel JA. Leukotriene B4 induces airway hyperresponsiveness in dogs. J Appl Physiol. 1985; 59: 1941–1946. 84 Dahlen SE, Hedqvist P, Hammarstrom S, Samuelsson B. Leukotrienes are potent constrictors of human bronchi. Nature (London). 1980; 228: 484–486. 85 Sirois P, Roy S, Borgeat P. Specificity of receptors for leukotrienes A4, B4, C4, D4, E4 and histamine on the guinea-pig lung parenchyma. Effect of FPL-55712 and desensitization of the myotropic activity. Prostaglandins. 1983; 26: 91–101. 86 Krell RD, Osborn R, Vickery L, Falcone K, O'Donnell, Gleason J, Kinzig C, Bryan D. Contraction of isolated airway smooth muscle by synthetic leukotrienes C4 and D4. Prostaglandins. 1981; 22: 387–408. 87 Denzlinger C, Guhlmann A, Scheuber PH, Wilker D, Hammer DK, Keppler D. Metabolism and analysis of cysteinyl leukotrienes in the monkeys. J Biol Chem. 1986; 261: 15601–15606. 88 Ahmed T, Marchette B, Wasserman M, Wanner A, Yerger L. Differential effects of LTC4, LTD4, and LTE4 in the pulmonary and systemic vasculature of sheep. Eur J Respir Dis. (in press). 89 Smith LJ, Greenberer P, Patterson R, Krell R, Bernstein P. Airway response to inhaled leukotriene D4 in humans. Am Rev Respir Dis. 1985; 131: 368–372. 90 Kern R, Smith LJ, Patterson R, Krell RD, Bernstein PR. Characterization of the airway response to inhaled leukotriene D4 in normal subjects. Am Rev Respir Dis. 1986; 133: 1127–1132. 91 Lewis RA, Robin J. Arachidonic acid derivatives as mediators of asthma. J Allergy Clin Immunol. 1985; 76: 259–264. 92 Krilis S, Lewis RA, Corey EJ, Austen KF. Bioconversion of C- 6 sulfidopeptide leukotrienes by the responding guinea pig ileum determines the time course of its contraction. J Clin Invest. 1983; 71: 909–915. 93 Marom Z, Shelhamer JH, Back MK, Morton DR, Kaliner M. Slow-reacting substances, leukotrienes C4 and D4, increase the release of mucus from human airways in vitro. Am Rev Respir Dis. 1982; 126: 449–451. 94 Peatfield AC, Piper PJ, Richardson PS. The effect of leukotriene C4 on mucin release into the cat trachea in vitro and in vivo. Br J Pharmacol. 1982; 77: 391–393. 95 Phipps RJ, Denas S, Wanner A. Leukotriene D4 stimulates secretion of glycoproteins, ions and water in sheep trachea (Abstract). Fed Proc. 1983; 42: 461. 96 Krell RD, Brown FJ, Willard AK, Giles RE. Pharmacologic antagonism of the leukotrienes. In: The Leukotrienes. New York: Academic Press. 1984; 271–298. 97 Russi EW, Abraham WM, Chapman GA, Stevenson JS, Codias E, Wanner A. Effects of leukotriene D4 on mucociliary and respiratory function in allergic and nonallergic sheep. J Appl Physiol. 1985; 59: 1416–1422. 98 Goetzl EJ, Austen KF. Purification and synthesis of eosinophil tetrapeptides of human lung tissue: Identification as eosinophil chemotactic factor of anaphylaxis. Proc Natl Acad Sci USA. 1975; 72: 4123–4171. 99 Boswell RN, Austen KF, Goetzl EJ. Intermediate molecular weight eosinophil chemotactic factors in rat peritoneal mast cells: Immunologic release, granule association and determination of structural heterogeneity. J Immunol. 1978; 120: 15–20. 100 Metzger WJ, Richerson HB, Wasserman SI. Generation and partial characterization of eosinophil chemotactic activity and neutrophil chemotactic activity during early and late-phase asthmatic response. J Allergy Clin Immunol. 1986; 78: 282–290. 101 Atkins PC, Norman M, Zweiman B. Release of neutrophil chemotactic activity during immediate hypersensitivity reactions in humans. Ann Intern Med. 1977; 86: 415–418. 102 Atkins PC, Norman M, Zweiman B. Antigen-induced chemotactic activity in man: Correlation with bronchospasm and inhibition by disodium cromoglycate. J Allergy Clin Immunol. 1978; 64: 149–155. 103 Atkins PC, Norman M, Zweiman B, Rosenblum F. Further characterization and biologic activity of ragweed antigen-induced neutrophil chemotactic activity in man. J Allergy Clin Immunol. 1979; 64: 251–258. 104 Said SI. Vasoactive intestinal polypeptide (VIP): Current status. Peptides. 1984; 5: 143–150. 105 Lundberg JM, Franco-Cereceda A, Hua X, Hokfelt T, Fischer JA. Coexistence of substance P and calcitonin gene-related peptide-like immunoreactivities in sensory nerves in relation to cardiovascular and bronchoconstrictor effects of capsaicin. Eur J Pharmacol. 1985; 108: 315–319. 106 Foreman JC, Jordan CC. Histamine release and vascular changes induced by neuropeptides. Agents Action. 1983; 13: 105–111. 107 Ghatei MA, Shepard MN, O'Shaughnessy DJ, Adrian TE, McGregor GP, Polak JM, Bloom SR. Regulatory peptides in the mammalian respiratory tract. Endocrinology. 1982; 111: 1248–1254. 108 Pepys J, Hutchcroft BJ. Bronchial provocation tests in the etiologic diagnosis and analysis of asthma. Am Rev Respir Dis. 1975; 112: 829–859. 109 Booij-Noord H, Orie NGM, de Vries K. Immediate and late bronchial obstructive reactions to inhalation of house dust and protective effects of disodium cromoglycate and prednisolone. J Allergy Clin Immunol. 1976; 51: 905–1011. 110 Abraham WM, Delehunt JC, Yerger L, Marchette B. Characterization of a late phase pulmonary response after antigen challenge in allergic sheep. Am Rev Respir Dis. 1983; 128: 839–844. 111 Shampain MP, Behrens BL, Larsen GL, Henson PM. An animal model of late pulmonary responses to Alternaria challenge. Am Rev Respir Dis. 1982; 126: 493–498. 112 Hamel R, McFarlane CS, Ford-Hutchinson AW. Late pulmonary responses induced by Ascaris allergen in conscious squirrel monkeys. J Appl Physiol. 1986; 61: 2081–2087. 113 Abraham WM, Wanner A, Stevenson JS, Chapman GA. The effect of an orally active leukotriene D4/E4 antagonist, LY 171883, on antigen-induced airway responses in allergenic sheep. Prostaglandins. 1986; 31: 457–467. 114 Perruchoud AP, Yerger L, Abraham WM. Differential effects of aminophylline on the early and late antigen-induced bronchial obstruction in allergic sheep. Am Rev Respir Dis. 1984; 129: 282. 115 Perruchoud AP, Yerger L, Russi E, Stevenson JS, Abraham WM. Prevention of allergic late bronchial obstruction by metaproterenol. Am Rev Respir Dis. 1984; 129: 5. 116 Ahmed T, Abraham WM. Role of calcium-channel blockers in obstructive airway disease. Chest. 1985; 88: 142S–151S 117 Lanes S, Stevenson JS, Codias E, Hernandez A, Sielczak MW, Abraham WM. Effects of budesonide on late bronchial responses and the associated airway hyperresponsiveness in allergic sheep. In: JC Hogg, R Ellul-Micallef, R Brattsand, eds.: Glucocorticosteroids: Inflammation and Bronchial Hyperreactivity. Netherlands: Excerpta Medica. 1985; 38–50. 118 Abraham WM, Lanes S, Stevenson JS, Yerger LD. Effect of an inhaled glucocorticosteroid (budesonide) on post-antigen induced increases in airway responsiveness. Bull Eur Physiopathol Respir. 1986; 22: 387–392. 119 Lanes S, Stevenson JS, Codias E, Hernandez A, Sielczak MW, Wanner A, Abraham WM. Indomethacin and FPL-57231 inhibit antigen-induced airway hyperresponsiveness in sheep. J Appl Physiol. 1986; 61: 864–872. 120 Abraham WM, Russi E, Wanner A, Delehunt JC, Yerger LD, Chapman GA. Production of early and late pulmonary responses with inhaled leukotriene D4 in allergic sheep. Prostaglandins. 1985; 29: 715–726. 121 Abraham WM, Russi E, Wanner A, Delehunt JC, Yerger LD, Chapman GA. Production of early and late pulmonary responses with inhaled leukotriene D4 in allergic sheep. Prostaglandins. 1985; 29: 715–726. Citing Literature Volume4, Issue41988Pages 237-247 ReferencesRelatedInformation